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Background: The impact of delayed clinical in-stent restenosis on the late re-inter-
ventions (RI) rate is currently unknown. To address this issue, we analyzed the long-
term clinical outcome in patients undergoing stent implantation for single de novo
lesions who were event-free after one year of follow-up, with an especial emphasis on
the rate of delayed restenosis and disease progression.
Methods: Retrospective analysis in patients who underwent single-vessel stenting
from January 2004 to December 2006 (N¼1385). In order to control for confounders,
we excluded patients with multivessel disease and patients who had RI during their
ﬁrst year of follow-up (N¼1108). From November 2012 to March 2013, we contacted
all patients included in the study (n¼277) and collected the following events: cardiac
death, RI, target lesion RI (TLR) and RI to other coronary segments due to disease
progression. Very late TLR was deﬁned as TLR events occurring after 3 years of
follow-up, while isolated TLR was deﬁned as TLR events occurring without RI due to
concomitant disease progression.
Results: Mean age was 60.310.1 years, 20.6 % were females, 16.2% diabetics and
72% had an acute coronary syndrome. 21.5% received a drug-eluting stent and 78.5 %
a bare-metal stent (50.2 % to the left anterior descending, 26% to the circumﬂex and
23.8% to the right coronary artery). Follow-up was available in 97.9% (92% with 7
years, mean follow-up 6.33.2 years). During follow-up, 89.2% of patients had at
least one non-invasive exercise test during follow-up (mean test performed per patient
3.21.8), 19.8% of those patients had a positive ischemic test at follow-up. 37.9 %
(n¼105) of patients underwent diagnostic coronary angiography, while 16% (n¼44)
required RI (Table). Cardiac death occurred in 2.8% of patients.
Conclusions: 1) Disease progression in patients with single vessel obstructive coro-
nary artery disease is an infrequent phenomenon but constitutes the dominant cause
for late RI. 2) Delayed clinical restenosis is rare. It's very late manifestation, typically
due to in-sent neoartherosclerosis, appears to have a very low clinical impact at least
until the seventh year of follow-up.N % Total % RI
Disease
progression
37 13.3 84
TLR 16 5.8 36.3
Very late TLR 7 2.5 15.9
Isolated TLR 7 2.5 15.9
Very late, isolated
TLR
3 1.1 6.8
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Background: In the drug-eluting stent era, in-stent restenosis (ISR) followed by a new
ISR recurrence, is deﬁned "resistant" ISR (R-ISR). This event represents a rare yet
challenging clinical problem. To date there are no published studies that evaluated the
best percutaneous treatment for these patients.
Methods: We identiﬁed 213 lesions in 201 patients treated with DES who presented
with R-ISR between 2003 and 2011 at our institution. The "balloon only" approach
with cutting, scoring or non-compliant balloon (n¼107, 53%) was compared with
coronary stent implantation (n¼94, 47%) in terms of target vessel revascularization
(TVR), target vessel failure (TVF), and a composite of major adverse cardiac event
(MACE) as death, myocardial infarction (MI) at 1-year.
Results: The baseline clinical characteristics were well balanced between two
percutaneous coronary intervention strategies. However the patients treated with
"balloon-only" presented with a worse baseline TIMI ﬂow (TIMI 0-1 13% vs. 5%,
P¼0.01), and had higher residual diameter stenosis post-PCI (19%  20 vs. 9%JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr11%, P<0.01). At 1-year follow-up, the rates of MACE, TVR, and TVF were not
signiﬁcantly different among the two strategies (Figure 1.).
Conclusions: Clinical outcomes after treatment of R-ISR with new stent implan-
tation does not appear to differ signiﬁcantly compared to a "balloon only"
technique.TCT-482
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Background: In the drug-eluting stent era, in-stent restenosis (ISR) followed by
ISR recurrence, represents a rare yet challenging clinical problem. The deﬁnition
and angiographic patterns of this phenomenon have not yet been reported.
Methods: We deﬁned "resistant" DES ISR (R-ISR) as the second occurrence of
ISR after initial successful treatment with DES. We identiﬁed 213 lesions in 201
patients treated with DES who presented with R-ISR between 2003 and 2011 at
our institution. We reviewed all angiograms to assess any patterns borne
from either the ﬁrst and second ISR episode as described by the Mehran
classiﬁcation.
Results: Patients with "resistant" ISR were more frequently male (72%) with
a mean age of 63 years. They presented with a very high frequency of diabetes
(56%), overweight (70%), and chronic kidney disease (35%). Most lesions were
bifurcation (55%) with moderate to severe calciﬁcation (58%). R-ISR presented
after 34 months from the ﬁrst procedure, with a focal pattern (10 mm in length)
in 78%, and diffuse pattern (>10 mm in length) in 22% of the patients. The rates
of all-cause mortality, MI, or target vessel failure (TVF) at 1-year were 4%, 3%,
and 18%, respectively. Patients with paclitaxel-eluting stent (PES) R-ISR showed
a higher rate of ischemic events compared with other type of stents at 1-year
follow-up (Table 1.).
Conclusions: Patients with "resistant" DES ISR comprise a very high-risk population
with suboptimal outcomes that are characterized by a high rate of ischemic adverse
events. R-ISR after PES appears to result in worse outcomes compared with other
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